Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant hepatitis B vaccine is a prophylactic agent used to prevent infection by the hepatitis B virus (HBV). It is composed of purified hepatitis B surface antigen (HBsAg) produced through recombinant DNA technology, typically expressed in yeast (*Saccharomyces cerevisiae*) or mammalian cell lines. The vaccine works by inducing the production of specific neutralizing antibodies (anti-HBs) in the recipient, providing active immunity against the virus. In clinical research conducted by Govind Ballabh Pant Hospital, this vaccine has been evaluated for its efficacy in preventing perinatal transmission of HBV from HBsAg-positive mothers to their newborns, comparing regimens of the vaccine alone against the combination of the vaccine with hepatitis B immune globulin (HBIG).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant hepatitis B vaccine (Govind Ballabh Pant Hospital).